Fevipiprant 150 mg + Fevipiprant 450 mg + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nasal Polyps
Conditions
Nasal Polyps
Trial Timeline
Mar 26, 2019 → Jun 10, 2020
NCT ID
NCT03681093About Fevipiprant 150 mg + Fevipiprant 450 mg + Placebo
Fevipiprant 150 mg + Fevipiprant 450 mg + Placebo is a phase 3 stage product being developed by Novartis for Nasal Polyps. The current trial status is completed. This product is registered under clinical trial identifier NCT03681093. Target conditions include Nasal Polyps.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03681093 | Phase 3 | Completed |
Competing Products
20 competing products in Nasal Polyps